Patent Ductus Arteriosus (PDA)
Patent ductus arteriosus (PDA) entails a failure of the hemodynamic adaptation to extrauterine life and is the most frequently seen cardiovascular problem in premature newborns. Protheragen is a world-leading one-stop service supplier for rare cardiovascular diseases like PDA. We provide comprehensive drug discovery and development solutions, with well-designed research plans for diagnostic and therapeutic purposes.
Introduction to Patent Ductus Arteriosus (PDA)
The ductus arteriosus (DA) is a fetal vessel, that diverts blood flow past the non-aerated lungs, supplying oxygenated blood from the placenta to the systemic circulation and shielding the immature pulmonary vascular vasculature in utero. At birth, rising oxygen tension and reduction in prostaglandins, and other dilatory substances result in contraction, closure, and ultimate fibromuscular remodeling of the DA to the ligamentum arteriosum. The interruption of the postnatal DA closure mechanism may result in pathological PDA with deleterious effects in neonates.
Fig.1 Molecular pathways involved in postnatal DA constriction. (Backes, C. H., et al., 2022)Prevalence PDA in term infants is reported to occur in one in 2000 births and 5% to 10% of all cases of congenital heart disease, and PDA is particularly challenging for preterm and, in particular, for low birthweight neonates.
Pathogenesis of Patent Ductus Arteriosus (PDA)
The genetic etiology of PDA is multifactorial and complex. The PDA might be 2 diseases because preterm and term PDA appear to be separate disorders; preterm PDA is caused by structural and functional immaturity of the ductus, whereas term PDA is caused by genetic abnormalities. PDA may be syndromic or nonsyndromic and syndromic PDA which contributes to most of the postnatal PDA seen in term infants is linked with chromosomal aneuploidy, chromosomal microdeletion, and single‐gene defects.
Fig.2 PDA configuration variations. (Backes, C. H., et al., 2022)Therapeutics Development for Patent Ductus Arteriosus (PDA)
| Drug Names | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| Indomethacin | Inhibits the synthesis of prostaglandins, which induces ductal closure. | COX | NCT04025177 | Phase II |
| Ibuprofen | A nonselective COX inhibitor, both acting to inhibit prostaglandin synthesis. | COX | NCT06601114 | N/A |
| Paracetamol | Facilitates closure of a patent ductus arteriosus by reducing the production of prostaglandins. | COX-2 | NCT06256211 | Phase I/II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
In the field of diagnostic and therapy research, our state-of-the-art utilities and services include the most recent developments in molecular biology and biomarker identification. We use our deep knowledge of cardiovascular to innovate and validate therapeutics that early detect. Furthermore, our strong suite of preclinical services offers specialized disease models for PDA and other cardiovascular diseases, detailed pharmacokinetic studies, and drug safety assessments.
Therapeutic Development Services
Animal Model Development for PDA
Animal models have helped in understanding the roles that molecular mediators play in the development and functioning of DAs. Our services for customized PDA animal model development services allow you to generate animal models that will suit your research very well and make it possible to increase success in your preclinical studies while using the in state-of-the-art technology.
Employing advanced methodology to simulate precisely the human manifestation of PDA in animal models by introducing specific genetic modifications.
- Ptger4 knockout model
- Ptgs2 knockout model
- Hpgd knockout model
- Slco2a1 knockout model
- Myh11 knockout model
- Other models
Combining cutting-edge science and a deep understanding of regulatory requirements, Protheragen supports our clients across the drug development life cycle, shortening the journey from concept to application. Our in-depth methodology guarantees that all solutions developed are adherent to the most stringent scientific standards of rigor and relevance. If you are interested in our service, contact us for more details.
Reference
- Backes, Carl H et al. "Patent Ductus Arteriosus: A Contemporary Perspective for the Pediatric and Adult Cardiac Care Provider." Journal of the American Heart Association 11.17 (2022): e025784.
For research use only, not for clinical use.